Canada Research Chair in Molecular Gyneco-Oncology, Research Group in Molecular Oncology and Endocrinology, Department of Medical Biology, Université du Québec à Trois-Rivières, Trois-Rivières, Québec, Canada G9A 5H7.
Gynecol Oncol. 2013 Feb;128(2):335-43. doi: 10.1016/j.ygyno.2012.11.016. Epub 2012 Nov 19.
In tumors, upstream regulation of Akt is affected by oncogenic events which lead to its constitutive activation and promote cell survival. Since studies have demonstrated that the three Akt isoforms exhibit different physiological functions, Akt isoforms may contribute differently in chemoresistance. The objective of the study was to determine the role of each Akt isoforms in chemoresistance.
We stably transfected the chemoresistant KLE endometrial carcinoma cells with specific shRNAs for Akt1, Akt2 or Akt3. Alternatively, we stably transfected the chemosensitive Hec-1-A endometrial carcinoma cells, in which no Akt activity is detected, with constitutively active Akt expression vectors for each isoform.
We demonstrated that Akt1 and Akt2 downregulation by RNAi highly sensitizes KLE cells to cisplatin by inducing the activation of pro-apoptotic factors such as the cleavage of caspases-3, -6, -9 and PARP; downregulation of all Akt isoforms leads to increased sensitivity to doxorubicin while only Akt1-2 downregulation increases taxol sensitivity. Proliferation of Akt1, and mostly Akt2 deficient cells was affected by cisplatin treatment. Constitutive Akt1 or Akt2 expression led to an increased resistance to apoptosis. Akt isoforms have been shown to influence migration in other cancer cells. We showed that Akt2 blocks cell motility, while Akt1-3 had less effect on our endometrial cancer cell models.
Our findings highlight the contribution of Akt1 and Akt2 in the molecular mechanisms that govern chemoresistance of endometrial carcinomas. Furthermore, Akt isoform-specific transfectants will provide a strong model to determine the involvement of each Akt isoform in tumor progression and metastasis.
在肿瘤中,Akt 的上游调节受致癌事件的影响,导致其组成性激活并促进细胞存活。由于研究表明三种 Akt 同工型表现出不同的生理功能,因此 Akt 同工型在化疗耐药性中可能有不同的作用。本研究的目的是确定每种 Akt 同工型在化疗耐药性中的作用。
我们用针对 Akt1、Akt2 或 Akt3 的特异性 shRNA 稳定转染耐药性 KLE 子宫内膜癌细胞。或者,我们用每个同工型的组成型活性 Akt 表达载体稳定转染无 Akt 活性的化疗敏感 Hec-1-A 子宫内膜癌细胞。
我们证明 Akt1 和 Akt2 的 RNAi 下调通过诱导促凋亡因子的激活(如 caspase-3、-6、-9 和 PARP 的切割),使 KLE 细胞对顺铂高度敏感;下调所有 Akt 同工型可增加对阿霉素的敏感性,而仅 Akt1-2 下调可增加紫杉醇的敏感性。Akt1 和 Akt2 缺陷细胞的增殖受到顺铂处理的影响。组成型 Akt1 或 Akt2 表达导致对凋亡的抵抗力增加。已经表明 Akt 同工型会影响其他癌细胞的迁移。我们表明 Akt2 阻断细胞迁移,而 Akt1-3 对我们的子宫内膜癌细胞模型的影响较小。
我们的研究结果强调了 Akt1 和 Akt2 在调节子宫内膜癌化疗耐药性的分子机制中的贡献。此外,Akt 同工型特异性转染体将为确定每个 Akt 同工型在肿瘤进展和转移中的参与提供一个强大的模型。